This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Telekom Malaysia Bhd (July 13, RM3.62) Maintain hold with a lower target price (TP) of RM3.55: Telekom Malaysia Bhd’s (TM) existing unifi Home subscribers will see an eight to 10 times speed upgrade (subject to technical availability) for the same price starting mid-August 2018, with the lowest-end package at RM129 for 100Mbps.
KUALA LUMPUR (July 13): Communications and Multimedia Minister Gobind Singh Deo has called on other telecommunication (telco) players to follow Telekom Malaysia Bhd (TM)'s move by cutting the price of their broadband offerings.
KUALA LUMPUR (July 13): Communications and Multimedia Minister Gobind Singh Deo said today he hoped that all telco companies will come up with a proposal soon on ways to reduce the price of broadband and increase the speed of the facility.
KUALA LUMPUR, July 13 — Communications and Multimedia Minister Gobind Singh Deo said today he hoped that all telco companies will come up with a proposal soon on ways to reduce the price of broadband and increase the speed of the facility.
KUALA LUMPUR (July 13): The FBM KLCI rose 0.74% at midday break today, tracking gains at most regional markets, lifted by factors including key heavyweight index-linked stocks.
7052 UPBMF 5681 9679 2089 CIMDF 1023 3204 4863 5347 3867 0026 TNABY 6888 4723 AXXTF MYTEF TNABF GEBHF
From Right: Datuk Bazlan Osman, acting group CEO, TM and Imri Mokhtar, executive vice president, Unifi, TM make a conference call to media members about Unifi's new broadband plans.
KUALA LUMPUR (July 12): Telekom Malaysia Bhd (TM) has unveiled a new entry-level broadband-only plan that is priced at RM79 per month and is exclusive for the bottom 40% (B40) income group with a household monthly income of below RM4,500.
The market failed to rebound last week despite finding some support two weeks ago. Market sentiment was still bearish on extended US-China trade war. Asian markets were the main casualties. The FBM KLCI fell 1.6% in a week to 1,663.86 points last Friday. The index rebounded this week and closed at 1,687.13 points yesterday.
4863 6888 AXXTF MYTEF 7277
SINGAPORE, July 10 — Most South-east Asian stock markets climbed today, with Singapore and Indonesia extending their rally, as US stocks gained overnight on hopes of strong corporate earnings, boosting positive sentiment across Asia.
WFCNP C.WSA WFC.PRL WFC.PRJ WFC.PRT C.WS.B WFC.PRR D05 WFC.PRQ WFC.PRP WFC.PRO DBSDF WFC.PRN C.WS.A C.PRP C.PRU MYTEF WFC.PRY WFC.PRX WFC.PRW WFC.PRV C.PRS WFC WFC.WS DBSDY C C.PRL C.PRJ C.PRK C.PRG O39 C.PRC 4863 C.PRPCL CGBBW
8h - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
9h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET